Keros Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 6, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 6, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Other Information
ITEM 5. OTHER INFORMATION
Rule 10b5-1 Trading Arrangements
During the three months ended September 30, 2024, the following officers of the Company adopted a “Rule 10b5-1 trading arrangement” as that term is defined in Item 408(a) of Regulation S-K, all of which were entered into during an open trading window in accordance with the Company’s Insider Trading Policy and all of which were intended to satisfy Rule 10b5-1(c):
On August 12, 2024, Keith Regnante, our Chief Financial Officer, adopted a Rule 10b5-1 trading plan that provides for the sale of up to 72,052 shares of common stock vested under outstanding stock options. The plan will expire on November 8, 2025, subject to early termination for certain specified events set forth in the plan.
On August 12, 2024, Christopher Rovaldi, our President and Chief Operating Officer, adopted a Rule 10b5-1 trading plan that provides for the sale of up to 85,306 shares of common stock vested under outstanding stock options. The plan will expire on November 15, 2025, subject to early termination for certain specified events set forth in the plan.
Except as set forth above, no director or officer of the Company adopted orterminated a “Rule 10b5-1 trading arrangement” or “non-rule 10b5-1 trading arrangement,” as each term is defined in item 408(a) of Regulation S-K, during the three months ended September 30, 2024.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.